MM
Moehler, M.
4 papers · 248 citations · 2023–2025
Publications
4
Citations
248
Years
2
Publications
| Title | Year | Type | Citations |
|---|---|---|---|
|
Event-free survival (EFS) and patient-reported outcomes (PROs) in MATTERHORN: A randomised, phase III study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) chemotherapy in resectable gastric/ gastroesophageal junction (G/GEJ) adenocarcinoma
|
2025 | Meeting Abstract | 4 |
|
Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer
|
2025 | Article | 161 |
|
Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study
|
2023 | Meeting Abstract | 11 |
|
Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study
|
2023 | Meeting Abstract | 72 |